Assembly Biosciences to Highlight Innovations in Palliative Care at 2026 Annual Assembly
- The 2026 Annual Assembly of Hospice and Palliative Care will be held in San Diego from March 4-7.
- Keynote session will focus on "Dementia-Specific Palliative Care," featuring experts like Dr. Laura Hanson.
- The assembly emphasizes innovative practices and collaboration to improve patient care in hospice and palliative settings.
Innovative Approaches in Palliative Care Highlighted at Upcoming Assembly
The upcoming 2026 Annual Assembly of Hospice and Palliative Care, hosted by the American Academy of Hospice and Palliative Medicine (AAHPM) and the Hospice & Palliative Nurses Association (HPNA), is set to take place from March 4-7, 2026, at the San Diego Convention Center. This three-day event is anticipated to attract over 3,000 healthcare professionals dedicated to enhancing the field of hospice and palliative care. With its focus on networking, sharing best practices, and discussing cutting-edge scientific research, the assembly serves as a pivotal platform for professionals aiming to improve patient care.
Among the notable features of this assembly is a keynote session centered on "Dementia-Specific Palliative Care," which will showcase a panel of distinguished experts, including Dr. Laura Hanson and Dr. Greg Sachs. This session aims to explore innovative methodologies for integrating evidence-based practices into care across diverse settings, emphasizing the importance of tailored approaches for patients suffering from dementia. The assembly also offers Deep Dive panels that will delve into critical subjects such as opioid conversion calculations and navigating complex issues like suicidality in serious illness care. AAHPM's CEO, Pierre Désy, expresses enthusiasm for the event, highlighting its potential to foster impactful conversations and celebrate key achievements in the field.
In addition to the main conference sessions, pre-conference workshops scheduled for March 4 will further enrich attendees’ learning experiences. These workshops are designed to provide in-depth knowledge and practical tools that professionals can apply in their work. Co-chairs R. Morgan Bain and Michelle Webb stress the assembly's commitment to delivering high-quality content and education rooted in scientific research. This event not only represents an opportunity for healthcare professionals to collaborate but also aims to drive advancements in patient care within the hospice and palliative care sectors.
The assembly serves as a crucial venue for healthcare professionals to stay informed about the latest developments and best practices in palliative care. With a focus on enhancing patient outcomes and addressing the evolving challenges within the healthcare landscape, the event underscores a collective commitment to advancing the standards of care in this essential field.
As the palliative care community gears up for this significant event, the anticipation surrounding the assembly reflects a broader movement towards improving quality of life for patients with serious illnesses, underscoring the ongoing need for innovation and collaboration in healthcare.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…